Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.42 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9012951 | 0.89 | PTGS2 (0.42) | PTGS2PTGS1CCR2 | |
| SCHEMBL5790164 | 0.87 | PTGS2 (0.41) | PTGS2PTGS1 | |
| SCHEMBL9012776 | 0.84 | PTGS2 (0.39) | PTGS2PTGS1 | |
| SCHEMBL9012601 | 0.83 | LMNA (0.34) | PTGS2 | |
| SCHEMBL5790937 | 0.82 | KDM4E (0.44) | PTGS2PTGS1CCR2 | |
| SCHEMBL9012694 | 0.82 | PTGS2 (0.44) | PTGS2PTGS1CCR2 | |
| SCHEMBL6402326 | 0.81 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL6044343 | 0.79 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL9012907 | 0.78 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL16719622 | 0.78 | PTGS2 (0.40) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1332661-C | Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors | SEARLE & CO (US) | 2007-08-22 | — | — | CN | claimed |
| CN-1660083-A | Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia | G D SIORL & CO (US) | 2005-08-31 | — | — | CN | claimed |
| CN-1253502-A | Method for preventing cardiovascular diseases using cyclooxygenase-2 inhibitor | SEARLE & CO (US) | 2000-05-17 | — | — | CN | claimed |
| CN-1244122-A | Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors | SEARLE & CO (US) | 2000-02-09 | — | — | CN | claimed |
| CN-100558356-C | The method that using cyclooxygenase-2-inhibitor 2 treatment and prophylaxis of tumours form | G D SIORL & CO (US) | 2009-11-11 | — | — | CN | disclosed |
| CN-100457183-C | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2009-02-04 | — | — | CN | disclosed |
| CN-1332661-C | Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors | SEARLE & CO (US) | 2007-08-22 | — | — | CN | disclosed |
| CN-1726018-A | Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents | PHARMACIA CORP (US) | 2006-01-25 | — | — | CN | disclosed |
| CN-1726030-A | Combinations of valsartan with cox-2 inhibitors | NOVARTIS AG (CH) | 2006-01-25 | — | — | CN | disclosed |
| CN-1660083-A | Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia | G D SIORL & CO (US) | 2005-08-31 | — | — | CN | disclosed |
| CN-1658853-A | Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (COX 2) inhibitor(s) | PHARMACIA CORP (US) | 2005-08-24 | — | — | CN | disclosed |
| US-20050113376-A1 | Compositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION | 2005-05-26 | — | — | US | disclosed |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| CN-1578674-A | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2005-02-09 | — | — | CN | disclosed |
| CN-1253502-A | Method for preventing cardiovascular diseases using cyclooxygenase-2 inhibitor | SEARLE & CO (US) | 2000-05-17 | — | — | CN | disclosed |
| CN-1244122-A | Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors | SEARLE & CO (US) | 2000-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | TPH2, TPH1, HTR2A | PTGS2 15/4885PTGS1 23/4885CCR2 2526/4885 |
| US-20050113376-A1 | Compositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury | XDH, PTGS2, PTGS1 | PTGS2 2/4885PTGS1 3/4885CCR2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.